FDA approves 1st ALS treatment in 22 years

The Food and Drug Administration on Friday approved Radicava — a new treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease.

Here are five things to know.

1. Radicava marks the first FDA-approved ALS treatment since riluzole hit the market in 1995, reports CNN.

2. The intravenous drug, developed by MT Pharma America, is administered daily in two-week treatment cycles.

3. The drug's list price is $1,000 per infusion, which totals nearly $150,000 annually, according to CNN.

4. Clinical trials conducted in Japan show patients taking Radicava had slower disease progression than those taking a placebo.

5. Jersey City, N.J.-based MT Pharma expects Radicava to hit the market in August.

More articles on supply chain:

Blue Cross member plans spent 73% more on drugs in 2016 than 2010
Supply chain tip of the week: Using the right equipment suppliers at the right time
Forget clothes — this thrift shop sells medical equipment

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars